Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
Authors:
Open Access
- 31 October 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 964824
Abstract
The current clinical management model of HER2-positive breast cancers is commonly based on guidelines, which in turn are based on the design and outcome of clinical trials. While this model is useful to most practicing clinicians, the treatment outcome of individual patient is not certain at the start of treatment. As the understanding of the translational research of carcinogenesis and the related changes in cancer genetics and tumor microenvironment during treatment is critical in the selection of right choice of treatment to maximize the successful clinical outcome for the patient, this review article intends to discuss the latest developments in the genetic and molecular mechanisms of cancer progression and treatment resistance, and how they influence the planning of the treatment strategies of HER2-positive breast cancers.Keywords
This publication has 123 references indexed in Scilit:
- The Human Splice Variant Δ16HER2 Induces Rapid Tumor Onset in a Reporter Transgenic MousePLOS ONE, 2011
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerOncogene, 2011
- Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 ReceptorClinical Cancer Research, 2010
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJournal of Clinical Oncology, 2009
- Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKαOncogene, 2009
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKKGenes & Development, 2008
- Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activityProceedings of the National Academy of Sciences, 2007
- Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast CancerJNCI: Journal of the National Cancer Institute, 2007
- Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translationThe EMBO Journal, 2006